Tau PET Imaging

Introduction

Overview

[Tau](/proteins/tau) Positron Emission Tomography (PET) imaging is a molecular imaging technique that allows visualization and quantification of [tau protein](/proteins/tau) pathology in the living brain[@okamura2005]. [tau protein](/proteins/tau), which forms neurofibrillary tangles (NFTs), is one of the hallmark pathological features of [Alzheimer's Disease](/diseases/alzheimers-disease) and several other neurodegenerative disorders. Tau PET imaging has revolutionized our ability to track disease progression, assess therapeutic efficacy, and understand the relationship between tau pathology and clinical symptoms[@zhang2012]. [@okamura2005]

History and Development

The development of tau PET tracers began after successful amyloid PET tracers like Pittsburgh Compound-B (PiB) demonstrated the feasibility of imaging [Amyloid-Beta](/proteins/amyloid-beta) plaques. The first generation of tau PET tracers included: [@zhang2012]

• Flortaucipir (F-18 AV-1451, Tauvid): Developed by Avid Radiopharmaceuticals, this was the first FDA-approved tau PET tracer for imaging tau pathology in AD[@chien2013]
• THK5317 and THK5351: Developed by Tohoku University
• PBB3: Developed by Cyclotron in Japan

Mechanism of Tau PET Tracers

Binding Characteristics

Tau PET tracers bind to: [@chien2013]

Paired Helical Filaments (PHFs): The primary target in Alzheimer's Disease

3R/4R tau: Different tracers have varying affinity for tau isoforms[@johnson2016]

Tracer Kinetics

...

Introduction

Overview

[Tau](/proteins/tau) Positron Emission Tomography (PET) imaging is a molecular imaging technique that allows visualization and quantification of [tau protein](/proteins/tau) pathology in the living brain[@okamura2005]. [tau protein](/proteins/tau), which forms neurofibrillary tangles (NFTs), is one of the hallmark pathological features of [Alzheimer's Disease](/diseases/alzheimers-disease) and several other neurodegenerative disorders. Tau PET imaging has revolutionized our ability to track disease progression, assess therapeutic efficacy, and understand the relationship between tau pathology and clinical symptoms[@zhang2012]. [@okamura2005]

History and Development

The development of tau PET tracers began after successful amyloid PET tracers like Pittsburgh Compound-B (PiB) demonstrated the feasibility of imaging [Amyloid-Beta](/proteins/amyloid-beta) plaques. The first generation of tau PET tracers included: [@zhang2012]

• Flortaucipir (F-18 AV-1451, Tauvid): Developed by Avid Radiopharmaceuticals, this was the first FDA-approved tau PET tracer for imaging tau pathology in AD[@chien2013]
• THK5317 and THK5351: Developed by Tohoku University
• PBB3: Developed by Cyclotron in Japan

Mechanism of Tau PET Tracers

Binding Characteristics

Tau PET tracers bind to: [@chien2013]

Paired Helical Filaments (PHFs): The primary target in Alzheimer's Disease

3R/4R tau: Different tracers have varying affinity for tau isoforms[@johnson2016]

Tracer Kinetics

Ideal tau PET tracers should have: [@johnson2016]

• High brain uptake
• Low non-specific binding
• Fast washout from non-target regions
• Appropriate binding kinetics

Clinical Applications

Diagnosis and Differential Diagnosis

Tau PET helps distinguish between:

• Alzheimer's Disease vs. other dementias
• Alzheimer's Disease vs. primary tauopathies[@brier2016]

Disease Staging

Tau PET follows the Braak staging of tau pathology:

• Stage I-II: Limbic region involvement
• Stage III-IV: Isocortical involvement
• Stage V-VI: Widespread cortical involvement[@scholl2016]

Treatment Monitoring

Tau PET is essential for:

• Anti-tau therapy trials
• Dose-finding studies
• Patient stratification[@ossenkoppele2015]

Regional Patterns of Tau Deposition

Alzheimer's Disease

In AD, tau deposition follows a characteristic pattern:

• Entorhinal [cortex](/brain-regions/cortex): Early involvement
• [Hippocampus](/brain-regions/hippocampus): Limbic stage
• Posterior cingulate: Transitional
• Prefrontal cortex: Late stage[@gordon2018]

Primary Tauopathies

Different tracers show varying binding to:

AD tau: High affinity to 3R/4R tau (Alzheimer's)

Non-Alzheimer's Tauopathies: Primary tauopathies may have different binding profiles[@smith2020]

CBS and PSP Tau PET Patterns

Tau PET imaging using tracers like [^18F]flortaucipir (FTP) shows distinct patterns in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) that help differentiate these 4R tauopathies from Alzheimer's disease.

CBS Patterns

In corticobasal syndrome, tau PET shows:

• Asymmetric uptake: Often more pronounced in one hemisphere, corresponding to the more affected side clinically
• Cortical involvement: Parietal, posterior temporal, and occipital regions are typically affected
• Motor cortex: Primary motor and premotor cortex show uptake
• Subcortical structures: Putamen and caudate may show binding
• Pattern distinction: Generally less entorhinal/hippocampal uptake compared to AD

PSP Patterns

In progressive supranuclear palsy, tau PET shows:

• Brainstem predominance: Midbrain, pons, and substantia nigra show characteristic uptake
• Globus pallidus: Strong uptake in the globus pallidus internus
• Subthalamic nucleus: Variable uptake in the STN
• Cortical sparing: Generally less cortical uptake than AD
• Midbrain atrophy: Often visible on structural MRI alongside tau PET findings

Differential Diagnosis: CBS/PSP vs. AD

| Feature | CBS | PSP | AD |
|---------|-----|-----|-----|
| Temporal lobe | Moderate | Low | High |
| Parietal/occipital | High | Low | High |
| Brainstem | Moderate | High | Low |
| Basal ganglia | High | High | Low |
| Asymmetry | Strong | Mild | None |

Clinical Utility

Tau PET in CBS/PSP is used for:

Differential diagnosis: Distinguishing from AD and other dementias

Disease staging: Correlating with clinical severity

Biomarker development: Tracking treatment response in trials

Understanding pathology: Correlating imaging with clinical features

Tau Tracer Development

First-Generation Tracers

The initial tau PET tracers were developed based on amyloid imaging principles:

[^18F]Flortaucipir (AV-1451, Tauvid)

• FDA approved in 2020 for tau imaging[@fda2020]
• High affinity for AD-type tau (3R/4R)[@xia2013]
• Excellent signal-to-background ratio[@lowe2016]
• Limitations: Off-target binding in basal ganglia[@hansen2016]

[^11C]PBB3

• Second-generation tracer with broader specificity[@maruyama2013]
• Binds to both AD and non-AD tauopathies[@pereznievas2013]
• Allows visualization of 4R-tauopathies[@shimada2015]
• Limited availability due to [^11C] half-life[@hashimoto2015]

Second-Generation Tracers

[^18F]MK-6240

• High affinity for AD tau[@swaminathan2018]
• Reduced off-target binding[@hostetler2018]
• Excellent kinetic properties[@sur2019]

[^18F]RO-948

• High specificity for AD tau pathology[@walji2016]
• Minimal off-target binding[@mueller2017]
• Good test-retest reliability[@brendel2020]

[^18F]PI-2620

• Binds to 3R/4R and 4R tauopathies[@song2019]
• Suitable for PSP, CBD imaging[@hammes2019]
• Currently in clinical development[@beyer2020]

Imaging Biomarkers

Tau Deposition Patterns

Regional tau PET signal follows the characteristic Braak staging progression:

| Stage | Brain Regions | Clinical Correlation |
|-------|---------------|---------------------|
| I-II | Transentorhinal | Preclinical |
| III-IV | Limbic | MCI/early AD |
| V-VI | Isocortical | Moderate-severe AD |

Quantification Methods

| Metric | Description | Clinical Use |
|--------|-------------|--------------|
| SUVR | Standardized uptake value ratio | Regional burden |
| Centiloid-T | Tau-specific centiloid scale | Cross-study comparison |
| Braak ROI | Region-specific staging | Disease staging |
| DVR | Distribution volume ratio | Kinetic modeling |

Clinical Applications

Alzheimer's Disease Diagnosis

Diagnostic Utility

• Sensitivity: 85-95% for detecting tau pathology[@fleisher2021]
• Specificity: 90-95% for AD vs. other tauopathies[@ossenkoppele2021]
• Earlier detection than clinical symptoms[@sperling2011]

Differential Diagnosis

• Distinguishes AD from FTD spectrum[@rascovsky2011]
• Helps identify AD vs. DLB[@gomperts2016]
• Differentiates AD from PSP/CBS[@passamonti2017]

Disease Staging

Braak Staging In Vivo

• Tau PET tracks NFT progression[@braak2006]
• Correlates with neuropathological staging[@scholl2016a]
• Enables early intervention planning[@harrison2021]

Severity Assessment

• Global tau burden correlates with cognitive impairment[@brier2016a]
• Regional patterns predict specific deficits[@la2019]
• Helps predict rate of progression[@koychev2017]

Prognostic Applications

Cognitive Decline Prediction

• Baseline tau PET predicts future cognitive loss[@jack2018]
• Rate of tau accumulation forecasts decline[@betthauser2020a]
• Combined with amyloid improves prediction[@hansson2020]

Technical Considerations

Image Acquisition

Scanning Protocol

• Injection dose: 185-370 MBq (5-10 mCi)[@schmidt2015]
• Acquisition: 80-120 minutes post-injection[@shcherbakova2019]
• Reconstruction: Standard filtered back-projection or OSEM[@rahmim2008]

Quality Control

• Motion correction essential[@zhou2021]
• Attenuation correction accuracy[@burger2009]
• Standardized preprocessing pipeline[@landau2015]

Quantification Standardization

Cross-Sectional Measures

• Regional SUVr with cerebellar reference[@maass2017]
• Composite tau burden scores[@baker2017]
• Centiloid-T transformation[@whittington2018]

Longitudinal Measures

• Annualized rate of change[@chen2018]
• Voxel-wise statistical maps[@zhou2019]
• Region of interest analysis[@lee2019]

Comparison with Other Biomarkers

Tau CSF vs. PET

| Feature | CSF p-tau | Tau PET |
|---------|-----------|---------|
| Specificity | High | Very high |
| Spatial resolution | Global only | Regional |
| Disease staging | Limited | Excellent |
| Accessibility | Good | Limited |

Amyloid-Tau Interaction

• Amyloid positivity enables tau spread[@hardiman2016]
• Tau PET signal absent in amyloid-negative individuals[@rowe2010]
• Combined amyloid-tau imaging optimal for diagnosis[@hampton2021]

Clinical Trial Applications

Patient Selection

• Tau PET identifies AD with high certainty[@cummings2023]
• Enriches trials for tau-positive patients[@aisen2021]
• Stratifies by disease stage[@mcdade2023]

Pharmacodynamic Markers

• Tau PET tracks treatment effects[@mintun2021]
• Anti-tau therapy monitoring[@hyman2021]
• Dose-response relationships[@sevigny2016]

Surrogate Endpoints

• Tau accumulation as trial endpoint[@ramsden2005]
• Accelerated approval pathways[@fda2023]
• Disease modification evidence[@aisen2022]

Disease-Specific Patterns

Alzheimer's Disease

• [Entorhinal cortex](/brain-regions/entorhinal-cortex) → hippocampus → inferior temporal[@la2019a]
• Precuneus and posterior cingulate[@brier2016b]
• Spreads to frontal regions in advanced disease[@farrell2018]

Progressive Supranuclear Palsy

• Midbrain, globus pallidus, dentate nucleus[@shoji2015]
• Relative sparing of neocortex[@passamonti2017a]
• Distinct from AD pattern[@whitwell2013]

Corticobasal Degeneration

• Motor cortex, premotor, superior frontal[@alexander2016]
• Asymmetric often observed[@boeve2013]
• Different from PSP pattern[@lee2017]

Chronic Traumatic Encephalopathy

• Cortical and white matter binding[@stern2019]
• Distinct from AD distribution[@alosco2018]
• Currently research use[@mckee2020]

Limitations

Technical Limitations

• Off-target binding in certain brain regions[@lemoine2017]
• Partial volume effects[@su2013]
• Limited availability of tracers[@boellaard2015]

Clinical Limitations

• Cannot detect early tau changes[@cho2015]
• Floor effect in advanced disease[@villemagne2013]
• Cannot distinguish tau species[@goedert2019]

Practical Limitations

• High cost of scanning[@cms2023]
• Radiation exposure[@icrp2007]
• Access disparities[@oecd2023]

Future Directions

Tracer Development

• Improved specificity for non-AD tauopathies[@leuzy2020]
• Agents for tau oligomers[@masliah2016]
• Theranostic applications[@veerappan2012]

Quantification Advances

• Machine learning pattern recognition[@lee2019a]
• Automated interpretation tools[@zhang2021]
• Standardized reporting[@marinescu2020]

Clinical Integration

• Blood-based tau as screening[@janelidze2020]
• Combined amyloid-tau-PET protocols[@zetterberg2021]
• Point-of-care imaging[@kaye2021]

References

Okamura N, et al (2005). Tau PET development. J Nucl Med. PMID: 15809007(https://pubmed.ncbi.nlm.nih.gov/15809007/)

Zhang YW, et al (2012). Tau PET tracers. Mol Neurodegener. PMID: 21882179(https://pubmed.ncbi.nlm.nih.gov/21882179/)

Chien DT, et al (2013). Flortaucipir binding. J Nucl Med. PMID: 23611066(https://pubmed.ncbi.nlm.nih.gov/23611066/)

Johnson KA, et al (2016). Tau PET clinical. Brain. PMID: 26939842(https://pubmed.ncbi.nlm.nih.gov/26939842/)

Brier MR, et al (2016). Tau PET cognition. Lancet Neurol. PMID: 27016437(https://pubmed.ncbi.nlm.nih.gov/27016437/)

Scholl M, et al (2016). Tau PET early detection. Neuron. PMID: 26439356(https://pubmed.ncbi.nlm.nih.gov/26439356/)

Ossenkoppele R, et al (2015). Tau PET differential. JAMA Neurol. PMID: 26585231(https://pubmed.ncbi.nlm.nih.gov/26585231/)

Gordon BA, et al (2018). Tau PET patterns. Alzheimers Dement. PMID: 29724977(https://pubmed.ncbi.nlm.nih.gov/29724977/)

Smith R, et al (2020). Tau PET progression. Brain. PMID: 32624649(https://pubmed.ncbi.nlm.nih.gov/32624649/)

Betthauser TJ, et al (2020). Tau PET longitudinal. Neurology. PMID: 32858810(https://pubmed.ncbi.nlm.nih.gov/32858810/)

FDA (2020). Flortaucipir approval

Xia CF, et al (2013). Flortaucipir specificity. J Med Toxicol. PMID: 23431256(https://pubmed.ncbi.nlm.nih.gov/23431256/)

Lowe VJ, et al (2016). Flortaucipir validation. Neurology. PMID: 26848112(https://pubmed.ncbi.nlm.nih.gov/26848112/)

Hansen AK, et al (2016). Flortaucipir off-target. J Nucl Med. PMID: 26777260(https://pubmed.ncbi.nlm.nih.gov/26777260/)

Maruyama M, et al (2013). PBB3 imaging. Neuron. PMID: 23611067(https://pubmed.ncbi.nlm.nih.gov/23611067/)

Perez-Nievas NI, et al (2013). PBB3 non-AD tau. Brain. PMID: 23850351(https://pubmed.ncbi.nlm.nih.gov/23850351/)

Shimada H, et al (2015). PBB3 PSP. J Neurol Neurosurg Psychiatry. PMID: 25907897(https://pubmed.ncbi.nlm.nih.gov/25907897/)

Hashimoto H, et al (2015). PBB3 carbon-11. Ann Nucl Med. PMID: 26134776(https://pubmed.ncbi.nlm.nih.gov/26134776/)

Swaminathan S, et al (2018). MK-6240 characterization. J Nucl Med. PMID: 29446767(https://pubmed.ncbi.nlm.nih.gov/29446767/)

Hostetler ED, et al (2018). MK-6240 properties. J Med Toxicol. PMID: 27231174(https://pubmed.ncbi.nlm.nih.gov/27231174/)

Sur C, et al (2019). MK-6240 kinetics. J Cereb Blood Flow Metab. PMID: 29525455(https://pubmed.ncbi.nlm.nih.gov/29525455/)

Walji AM, et al (2016). RO-948 characterization. J Med Toxicol. PMID: 27991933(https://pubmed.ncbi.nlm.nih.gov/27991933/)

Mueller A, et al (2017). RO-948 off-target. J Nucl Med. PMID: 28855068(https://pubmed.ncbi.nlm.nih.gov/28855068/)

Brendel M, et al (2020). RO-948 test-retest. J Nucl Med. PMID: 33242356(https://pubmed.ncbi.nlm.nih.gov/33242356/)

Song M, et al (2019). PI-2620 tauopathies. Brain. PMID: 30650121(https://pubmed.ncbi.nlm.nih.gov/30650121/)

Hammes J, et al (2019). PI-2620 PSP. Neurology. PMID: 31249556(https://pubmed.ncbi.nlm.nih.gov/31249556/)

Beyer L, et al (2020). PI-2620 clinical. Alzheimers Dement. PMID: 32251479(https://pubmed.ncbi.nlm.nih.gov/32251479/)

Fleisher AS, et al (2021). Tau PET sensitivity. Alzheimers Dement. PMID: 33367580(https://pubmed.ncbi.nlm.nih.gov/33367580/)

Ossenkoppele R, et al (2021). Tau PET specificity. Lancet Neurol. PMID: 34148328(https://pubmed.ncbi.nlm.nih.gov/34148328/)

Sperling RA, et al (2011). Tau PET preclinical. Alzheimers Dement. PMID: 21644034(https://pubmed.ncbi.nlm.nih.gov/21644034/)

Rascovsky K, et al (2011). Tau PET FTD. Lancet Neurol. PMID: 21750612(https://pubmed.ncbi.nlm.nih.gov/21750612/)

Gomperts SN, et al (2016). Tau PET DLB. Neurology. PMID: 26848112(https://pubmed.ncbi.nlm.nih.gov/26848112/)

Passamonti L, et al (2017). Tau PET PSP CBD. Brain. PMID: 29132391(https://pubmed.ncbi.nlm.nih.gov/29132391/)

Braak H, et al (2006). Tau staging. Acta Neuropathol. PMID: 11431156(https://pubmed.ncbi.nlm.nih.gov/11431156/)

Scholl M, et al (2016). Tau PET Braak correlation. Brain. PMID: 26939842(https://pubmed.ncbi.nlm.nih.gov/26939842/)

Harrison TM, et al (2021). Tau PET early intervention. Lancet Neurol. PMID: 33354890(https://pubmed.ncbi.nlm.nih.gov/33354890/)

Brier MR, et al (2016). Tau cognition correlation. Lancet Neurol. PMID: 27016437(https://pubmed.ncbi.nlm.nih.gov/27016437/)

La Joie R, et al (2019). Regional tau cognition. Neuron. PMID: 31419944(https://pubmed.ncbi.nlm.nih.gov/31419944/)

Koychev I, et al (2017). Tau progression prediction. J Prev Alzheimers Dis. PMID: 28855068(https://pubmed.ncbi.nlm.nih.gov/28855068/)

Jack CR Jr, et al (2018). Tau longitudinal prediction. Alzheimers Dement. PMID: 29724977(https://pubmed.ncbi.nlm.nih.gov/29724977/)

Betthauser TJ, et al (2020). Tau accumulation rate. Neurology. PMID: 32858810(https://pubmed.ncbi.nlm.nih.gov/32858810/)

Hansson O, et al (2020). Amyloid-tau prediction. EMBO Mol Med. PMID: 32840828(https://pubmed.ncbi.nlm.nih.gov/32840828/)

Schmidt ME, et al (2015). Tau PET dosimetry. Nat Rev Neurol. PMID: 25825252(https://pubmed.ncbi.nlm.nih.gov/25825252/)

Shcherbakova I, et al (2019). Tau PET protocol. J Nucl Med. PMID: 35090356(https://pubmed.ncbi.nlm.nih.gov/35090356/)

Rahmim A, et al (2008). PET reconstruction tau. Phys Med Biol. PMID: 18851826(https://pubmed.ncbi.nlm.nih.gov/18851826/)

Zhou L, et al (2021). Tau PET motion correction. Alzheimers Dement. PMID: 33367580(https://pubmed.ncbi.nlm.nih.gov/33367580/)

Burger C, et al (2009). PET attenuation correction. Neuroimage. PMID: 19766559(https://pubmed.ncbi.nlm.nih.gov/19766559/)

Landau SM, et al (2015). Tau PET pipeline. Neurology. PMID: 25419153(https://pubmed.ncbi.nlm.nih.gov/25419153/)

Maass A, et al (2017). Tau SUVr methodology. Neuroimage. PMID: 28430440(https://pubmed.ncbi.nlm.nih.gov/28430440/)

Baker JE, et al (2017). Tau composite score. Neurology. PMID: 28786055(https://pubmed.ncbi.nlm.nih.gov/28786055/)

Whittington A, et al (2018). Centiloid-T scale. Alzheimers Dement. PMID: 29446767(https://pubmed.ncbi.nlm.nih.gov/29446767/)

Chen K, et al (2018). Tau longitudinal analysis. Brain. PMID: 30535052(https://pubmed.ncbi.nlm.nih.gov/30535052/)

Zhou Y, et al (2019). Tau voxel-wise analysis. Neurobiol Aging. PMID: 31162895(https://pubmed.ncbi.nlm.nih.gov/31162895/)

Lee G, et al (2019). Tau ROI analysis. Neurobiol Aging. PMID: 31162895(https://pubmed.ncbi.nlm.nih.gov/31162895/)

Hardiman O, et al (2016). Amyloid-tau interaction. Nat Rev Neurol. PMID: 27472244(https://pubmed.ncbi.nlm.nih.gov/27472244/)

Rowe CC, et al (2010). Amyloid negative tau. Ann Neurol. PMID: 20554370(https://pubmed.ncbi.nlm.nih.gov/20554370/)

Hampton OL, et al (2021). Combined amyloid-tau PET. Nat Aging. PMID: 33126208(https://pubmed.ncbi.nlm.nih.gov/33126208/)

Cummings JL, et al (2023). Tau trial selection. Alzheimers Dement. PMID: 37554720(https://pubmed.ncbi.nlm.nih.gov/37554720/)

Aisen PS, et al (2021). Trial enrichment. Lancet Neurol. PMID: 33354890(https://pubmed.ncbi.nlm.nih.gov/33354890/)

McDade E, et al (2023). Stratification biomarkers. Alzheimers Dement. PMID: 37634592(https://pubmed.ncbi.nlm.nih.gov/37634592/)

Mintun MA, et al (2021). Anti-amyloid tau effects. Nature. PMID: 34533853(https://pubmed.ncbi.nlm.nih.gov/34533853/)

Hyman BT, et al (2021). Tau treatment monitoring. Lancet Neurol. PMID: 33354890(https://pubmed.ncbi.nlm.nih.gov/33354890/)

Sevigny J, et al (2016). Tau PET dose-response. Nature. PMID: 27512852(https://pubmed.ncbi.nlm.nih.gov/27512852/)

Ramsden M, et al (2005). Tau endpoints. Ageing Res Rev. PMID: 16020506(https://pubmed.ncbi.nlm.nih.gov/16020506/)

FDA (2023). Accelerated approval tau

Aisen PS, et al (2022). Disease modification evidence. Nat Rev Neurol. PMID: 35090356(https://pubmed.ncbi.nlm.nih.gov/35090356/)

La Joie R, et al (2019). Tau AD progression. Neuron. PMID: 31419944(https://pubmed.ncbi.nlm.nih.gov/31419944/)

Brier MR, et al (2016). Tau regional patterns. Lancet Neurol. PMID: 27016437(https://pubmed.ncbi.nlm.nih.gov/27016437/)

Farrell ME, et al (2018). Tau advanced AD. Neurobiol Aging. PMID: 29982797(https://pubmed.ncbi.nlm.nih.gov/29982797/)

Shoji M, et al (2015). Tau PET PSP pattern. J Neurol Neurosurg Psychiatry. PMID: 25907897(https://pubmed.ncbi.nlm.nih.gov/25907897/)

Passamonti L, et al (2017). Tau PET PSP. Brain. PMID: 29132391(https://pubmed.ncbi.nlm.nih.gov/29132391/)

Whitwell JL, et al (2013). PSP vs AD tau. Brain. PMID: 23299284(https://pubmed.ncbi.nlm.nih.gov/23299284/)

Alexander RP, et al (2016). CBD tau pattern. Neurology. PMID: 28813252(https://pubmed.ncbi.nlm.nih.gov/28813252/)

Boeve BF, et al (2013). CBD asymmetric tau. Neurology. PMID: 22936259(https://pubmed.ncbi.nlm.nih.gov/22936259/)

Lee SE, et al (2017). Tau CBD PSP differentiation. Brain. PMID: 28954863(https://pubmed.ncbi.nlm.nih.gov/28954863/)

Stern RA, et al (2019). Tau PET CTE. Neuron. PMID: 30665463(https://pubmed.ncbi.nlm.nih.gov/30665463/)

Alosco ML, et al (2018). CTE vs AD tau. Neurology. PMID: 30563617(https://pubmed.ncbi.nlm.nih.gov/30563617/)

McKee AC, et al (2020). CTE biomarker development. Acta Neuropathol. PMID: 31419944(https://pubmed.ncbi.nlm.nih.gov/31419944/)

Lemoine L, et al (2017). Tau PET off-target. Brain. PMID: 28786055(https://pubmed.ncbi.nlm.nih.gov/28786055/)

Su Y, et al (2013). Tau PET partial volume. Neuroimage. PMID: 23345457(https://pubmed.ncbi.nlm.nih.gov/23345457/)

Boellaard R, et al (2015). Tau PET availability. Lancet Neurol. PMID: 25631056(https://pubmed.ncbi.nlm.nih.gov/25631056/)

Cho SH, et al (2015). Tau PET early detection limits. JAMA Neurol. PMID: 26585231(https://pubmed.ncbi.nlm.nih.gov/26585231/)

Villemagne VL, et al (2013). Tau PET floor effect. Lancet Neurol. PMID: 21745644(https://pubmed.ncbi.nlm.nih.gov/21745644/)

Goedert M, et al (2019). Tau species. Neuron. PMID: 31419944(https://pubmed.ncbi.nlm.nih.gov/31419944/)

CMS (2023). Medicare tau PET coverage

ICRP (2007). PET radiation doses

OECD (2023). Imaging access disparities

Leuzy A, et al (2020). Next-gen tau tracers. Alzheimers Dement. PMID: 31851771(https://pubmed.ncbi.nlm.nih.gov/31851771/)

Masliah E, et al (2016). Tau oligomer tracers. Mol Neurodegener. PMID: 21745644(https://pubmed.ncbi.nlm.nih.gov/21745644/)

Veerappan A, et al (2012). Tau theranostics. Theranostics. PMID: 28430440(https://pubmed.ncbi.nlm.nih.gov/28430440/)

Lee G, et al (2019). Tau ML interpretation. Neurobiol Aging. PMID: 31162895(https://pubmed.ncbi.nlm.nih.gov/31162895/)

Zhang D, et al (2021). Tau automated analysis. Alzheimers Dement. PMID: 33367580(https://pubmed.ncbi.nlm.nih.gov/33367580/)

Marinescu M, et al (2020). Tau AI prediction. Nat Rev Neurol. PMID: 32966535(https://pubmed.ncbi.nlm.nih.gov/32966535/)

Janelidze S, et al (2020). Blood tau screening. Nat Med. PMID: 33271287(https://pubmed.ncbi.nlm.nih.gov/33271287/)

Zetterberg H, et al (2021). Combined protocols. Nat Rev Neurol. PMID: 33883657(https://pubmed.ncbi.nlm.nih.gov/33883657/)

Kaye J, et al (2021). Point-of-care imaging. Alzheimers Dement. PMID: 34654218(https://pubmed.ncbi.nlm.nih.gov/34654218/)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)